RT Journal Article
SR Electronic
T1 Single-gene transcripts for subclinical TB: an individual participant data meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.04.24309943
DO 10.1101/2024.07.04.24309943
A1 Greenan-Barrett, James
A1 Mendelsohn, Simon C.
A1 Scriba, Thomas J.
A1 Noursadeghi, Mahdad
A1 Gupta, Rishi K.
YR 2024
UL http://medrxiv.org/content/early/2024/07/07/2024.07.04.24309943.abstract
AB Background Translation of blood RNA signatures may be accelerated by identifying more parsimonious biomarkers. We tested the hypothesis that single-gene transcripts provide comparable accuracy for detection of subclinical TB to multi-gene signatures and benchmarked their clinical utility to interferon-y release assays (IGRAs).Methods We identified datasets where participants underwent RNA sampling and at least 12 months of follow-up for progression to TB. We performed a one-stage individual participant data meta-analysis to compare multi-gene signatures against single-gene transcripts to detect subclinical TB, defined as asymptomatic prevalent or incident TB (diagnosed ≥21 days from enrolment, irrespective of symptoms) over a 12-month interval. We performed decision curve analysis to evaluate the net benefit of using RNA biomarkers and IGRA, alone or in combination, compared to treating all or no individuals with preventative treatment.Results We evaluated 80 single-genes and eight multi-gene signatures in a pooled analysis of four RNAseq and three qPCR datasets, comprising 6544 total samples and including 283 samples from 214 individuals with subclinical TB. Five single-gene transcripts were equivalent to the best-performing multi-gene signature over 12 months, with areas under the receiver operating characteristic curves ranging from 0.75-0.77, but none met the WHO minimum target product profile (TPP) for a TB progression test. IGRA demonstrated much lower specificity in higher burden settings, while sensitivity and specificity of RNA biomarkers were consistent across settings. In higher burden settings, RNA biomarkers had greater net benefit than IGRA, which offered little clinical utility over treating all with preventative therapy. In low burden settings, IGRA approximated the TPP and offered greater clinical utility than RNA biomarkers, but combining both tests provided the highest net benefit for services aiming to treat <50 people to prevent a single case.Interpretation Single-gene transcripts are equivalent to multi-gene signatures for detection of subclinical TB, with consistent performance across settings. Single transcripts demonstrate potential clinical utility to stratify treatment, particularly when used in combination with IGRA in low burden settings.Competing Interest StatementMN holds a patent in relation to blood transcriptomic biomarkers of tuberculosis. TJS is co-inventor of patents of the Penn-Nicholson6 and Suliman4 signatures. All other authors declare no competing interests.Funding StatementRKG is funded by National Institute for Health Research (NIHR303184), the BMA Foundation for Medical Research and by NIHR Biomedical Research Funding to UCL and UCLH. MN was supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All included RNA datasets were publicly available before initiation of the study and are available through the original contributing studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data analysed in this study are publicly available through the original contributing studies.